Last reviewed · How we verify

Fentanyl TAIFUN

Akela Pharma, Inc. · Phase 3 active Small molecule

Fentanyl TAIFUN is a transdermal or inhalation formulation of fentanyl, a potent synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation.

Fentanyl TAIFUN is a transdermal or inhalation formulation of fentanyl, a potent synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation. Used for Moderate to severe pain (specific indication pending phase 3 results).

At a glance

Generic nameFentanyl TAIFUN
SponsorAkela Pharma, Inc.
Drug classOpioid analgesic (synthetic opioid)
TargetMu-opioid receptor (OPRM1)
ModalitySmall molecule
Therapeutic areaPain Management
PhasePhase 3

Mechanism of action

Fentanyl acts as a mu-opioid receptor agonist, activating inhibitory pathways in the spinal cord and brain that reduce pain signal transmission and perception. The TAIFUN formulation appears to be a delivery system variant designed to optimize pharmacokinetics and patient tolerability. By modulating opioid receptor signaling, fentanyl produces dose-dependent analgesia, sedation, and respiratory depression.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: